18 results on '"Heo, Gwangbeom"'
Search Results
2. Senescence marker protein 30 protects intestinal epithelial cells against inflammation-induced cell death by enhancing Nrf2 activity
- Author
-
Choo, Jieun, Heo, Gwangbeom, Kim, Su Jin, Lee, Yunna, Ishigami, Akihito, Maruyama, Naoki, Chung, Hae Young, and Im, Eunok
- Published
- 2018
- Full Text
- View/download PDF
3. Novel β-phenylacrylic acid derivatives exert anti-cancer activity by inducing Src-mediated apoptosis in wild-type KRAS colon cancer
- Author
-
Kim, Su Jin, Noh, Tae Hwan, Son, Sujin, Kim, Do Hyun, Kim, Wooseong, Lee, Yunna, Choo, Jieun, Heo, Gwangbeom, Kim, Min Jae, Chung, Hae Young, Jung, Yunjin, Jung, Jee Hyung, Moon, Hyung Ryong, and Im, Eunok
- Published
- 2018
- Full Text
- View/download PDF
4. Atractylodin Ameliorates Colitis via PPARα Agonism.
- Author
-
Heo, Gwangbeom, Kim, Yuju, Kim, Eun-La, Park, Soyeong, Rhee, Sang Hoon, Jung, Jee H., and Im, Eunok
- Subjects
- *
COLITIS , *PEROXISOME proliferator-activated receptors , *GASTROINTESTINAL diseases , *INFLAMMATORY bowel diseases , *BINDING site assay - Abstract
Atractylodin is a major compound in the rhizome of Atractylodes lancea, an oriental herbal medicine used for the treatment of gastrointestinal diseases, including dyspepsia, nausea, and diarrhea. Recent studies have shown that atractylodin exerts anti-inflammatory effects in various inflammatory diseases. Herein, we investigated the anti-colitis effects of atractylodin and its molecular targets. We determined the non-cytotoxic concentration of atractylodin (50 μM) using a cell proliferation assay in colonic epithelial cells. We found that pretreatment with atractylodin significantly inhibits tumor necrosis factor-α-induced phosphorylation of nuclear factor-κ-light-chain-enhancer of activated B in HCT116 cells. Through docking simulation analysis, luciferase assays, and in vitro binding assays, we found that atractylodin has an affinity for peroxisome proliferator-activated receptor alpha (PPARα). Daily administration of atractylodin (40 mg/kg) increased the survival rate of mice in a dextran sodium sulfate-induced colitis mouse model. Thus, atractylodin can be a good strategy for colitis therapy through inducing PPARα-dependent pathways. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
5. N‐Acetylserotonin is an oxidation‐responsive activator of Nrf2 ameliorating colitis in rats.
- Author
-
Kang, Changyu, Jeong, Seongkeun, Kim, Jaejeong, Ju, Sanghyun, Im, Eunok, Heo, Gwangbeom, Park, Soyeong, Yoo, Jin‐Wook, Lee, Juho, Yoon, In‐Soo, and Jung, Yunjin
- Subjects
NUCLEAR factor E2 related factor ,COLITIS - Abstract
N‐Acetylserotonin (NAS) is an intermediate in the melatonin biosynthetic pathway. We investigated the anti‐inflammatory activity of NAS by focusing on its chemical feature oxidizable to an electrophile. NAS was readily oxidized by reaction with HOCl, an oxidant produced in the inflammatory state. HOCl‐reacted NAS (Oxi‐NAS), but not NAS, activated the anti‐inflammatory nuclear factor erythroid 2‐related factor 2 (Nrf2)‐heme oxygenase (HO)‐1 pathway in cells. Chromatographic and mass analyses demonstrated that Oxi‐NAS was the iminoquinone form of NAS and could react with N‐acetylcysteine possessing a nucleophilic thiol to form a covalent adduct. Oxi‐NAS bound to Kelch‐like ECH‐associated protein 1, resulting in Nrf2 dissociation. Moreover, rectally administered NAS increased the levels of nuclear Nrf2 and HO‐1 proteins in the inflamed colon of rats. Simultaneously, NAS was converted to Oxi‐NAS in the inflamed colon. Rectal NAS mitigated colonic damage and inflammation. The anticolitic effects were significantly compromised by the coadministration of an HO‐1 inhibitor. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
6. 9: CHRONIC COLITIS IN MICE CAN CAUSE HMGB1-MEDIATED INFLAMMATORY RESPONSES IN THE BRAIN
- Author
-
Mitchell, Jonathon, Kim, Su Jin, Howe, Cody S., Kim, Gayoung, Heo, Gwangbeom, Jeong, Sihyun, Im, Eunok, and Rhee, Sang H.
- Published
- 2022
- Full Text
- View/download PDF
7. Su1090 ANTI-INFLAMMATORY EFFECTS OF ATRACTYLODIN VIA PPAR-ALPHA ON INTESTINAL INFLAMMATION
- Author
-
Heo, Gwangbeom, Kim, Su Jin, Lee, Yunna, Her, Ji Yun, Rhee, Sang H., and Im, Eunok
- Published
- 2020
- Full Text
- View/download PDF
8. Pro-apoptotic effect of the novel benzylidene derivative MHY695 in human colon cancer cells.
- Author
-
Heo, Gwangbeom, Kang, Dongwan, Park, Chaeun, Kim, Su Jin, Choo, Jieun, Lee, Yunna, Yoo, Jin-Wook, Jung, Yunjin, Lee, Jaewon, Kim, Nam Deuk, Chung, Hae Young, Moon, Hyung Ryong, and Im, Eunok
- Subjects
- *
COLON cancer , *CANCER cells , *TUMOR suppressor proteins , *PROTEIN kinase B , *P53 protein , *POLY ADP ribose , *POLYMERASES - Abstract
The induction of apoptosis is a useful strategy in anti-cancer research. Various Moon Hyung Yang (MHY) compounds have been developed as novel anti-cancer drug candidates; in the present study, the pro-apoptotic effects of (Z)-5-(3-ethoxy-4- hydroxybenzylidene)-2-thioxothiazolidin-4-one (MHY695) on HCT116 human colon cancer cells were assessed. MTT assays were performed to investigate the dose-dependent cytotoxic effects of MHY695 on HCT116 cells. Immunofluorescence staining and flow cytometry analyses were performed to identify apoptotic cell death, and western blot analysis was used to investigate the apoptotic-signaling pathways. A mouse xenograft model was also used to determine the effects of MHY695 in vivo. MHY695 decreased the viability of HCT116 cells and induced apoptotic cytotoxicity. The apoptotic mechanisms induced by MHY695 involved the dephosphorylation of Bcl-2-associated agonist of cell death protein following protein kinase B inactivation, induced myeloid leukaemia cell differentiation protein and BH3-interacting domain death agonist truncation, caspase-3 and −9 activation and poly (ADP-ribose) polymerase cleavage. In addition, MHY695 significantly suppressed tumor growth in the mouse xenograft model, compared with the vehicle control. Notably, MHY695 exhibited potent anti-cancer effects in four different types of human colon cancer cell line, including Caco-2, DLD-1, HT-29 and HCT116. Additionally, MHY695 showed reduced cytotoxicity in NCM460, normal colonic epithelial cells. Furthermore, MHY-induced cytotoxicity in colon cancer cells was independent of the tumor suppressor protein p53. Collectively, these observations suggested that MHY695 may be a novel drug for the treatment of colon cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
9. Analysis of endogenous lipids during intestinal wound healing.
- Author
-
Lee, Yunna, Choo, Jieun, Kim, Su Jin, Heo, Gwangbeom, Pothoulakis, Charalabos, Kim, Yong-Hak, and Im, Eunok
- Subjects
INTESTINAL injuries ,WOUND healing ,INFLAMMATORY bowel disease treatment ,DISEASE remission ,SODIUM sulfate ,THERAPEUTICS - Abstract
Intestinal wound healing is a new therapeutic goal for inflammatory bowel disease (IBD) as complete healing of the mucosa is the key element of clinical remission in IBD. Previous studies showed that termination of inflammation can be achieved by adding pro-resolving lipids like DHA and EPA exogenously. However, the roles of these lipids in mucosal healing have not been investigated. To recapitulate intestinal healing process, mice were received dextran sodium sulfate (DSS) for 7 days in the drinking water followed by regular tap water for 5 additional days. DSS-induced intestinal inflammation featuring body weight loss, histological tissue damage, increased cytokine production and infiltration of inflammatory cells was gradually reduced upon switching to water. To investigate whether endogenous lipids play a role in mucosal healing, the lipidomics analysis of mouse serum was performed. Reduced levels of arachidonic acid, the biosynthetic precursor of prostaglandin F (PGF)
2α , 19H-PGF1α , the metabolite of prostacyclin, and 20H-PGF2α , the metabolite of PGF2α , suggest subsiding inflammation. In contrast, increased levels of an active metabolite of resolvin D1 along with decreased levels of its precursor DHA as well as decreased levels of the precursor of resolvin E, 18-hydroxy-eicosapentaenoic acid, suggest inauguration of mucosal healing by endogenous lipids. Furthermore, exogenously supplied fish oil enhanced the process even further. These results suggest the presence of mucosal healing regulated by endogenous pro-healing lipids and also indicate that the remission state of IBD could be prolonged by enhancing the levels of these lipids. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
10. Neuroprotective effects of 2,4-dinitrophenol in an acute model of Parkinson’s disease.
- Author
-
Lee, Yujeong, Heo, Gwangbeom, Lee, Kyung Moon, Kim, Ah Hyun, Chung, Ki Wung, Im, Eunok, Chung, Hae Young, and Lee, Jaewon
- Subjects
- *
NEUROPROTECTIVE agents , *DINITROPHENOL , *PARKINSON'S disease , *HOMEOSTASIS , *NEURODEGENERATION - Abstract
Neurons depend on mitochondria for homeostasis and survival, and thus, mitochondrial dysfunction has been implicated in neurodegenerative diseases, including Parkinson’s disease (PD). Increasing evidence indicates the mitochondrial uncoupler, 2,4-dinitrophenol (DNP), protects neurons against neurodegeneration and enhances neural plasticity. Here, the authors evaluated the protective effects of intraperitoneally (i.p.) administered low dose DNP in an acute mouse model of PD. Mice were administered DNP (1 or 5 mg/kg) for 12 consecutive days, and then on day 13, MPTP (20 mg/kg, i.p.) was administered four times (with 2 h intervals between injections) to induce PD. It was found that MPTP-induced motor dysfunction was ameliorated in the DNP-treated mice versus vehicle-treated controls. Additionally, DNP effectively attenuated dopaminergic neuronal loss observed in MPTP treated mice. Moreover, in primary cultured neurons, DNP at 10 μM, but not at 100 μM, prevented MPP + -induced cell death and mitochondrial membrane potential (MMP) reduction. In addition, DNP was observed to cause the nuclear translocation of Nrf2 in primary neurons. Taken together, these findings of the present study suggest that DNP protects dopaminergic neurons against neurodegeneration and maintains MMP integrity in PD by activating adaptive stress responses. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
11. Modulation of Intestinal Epithelial Permeability via Protease-Activated Receptor-2-Induced Autophagy.
- Author
-
Kim, Yuju, Lee, Yunna, Heo, Gwangbeom, Jeong, Sihyun, Park, Soyeong, Yoo, Jin-Wook, Jung, Yunjin, and Im, Eunok
- Subjects
AUTOPHAGY ,ARRESTINS ,PERMEABILITY ,INTESTINES ,TIGHT junctions ,PROTEASE-activated receptors ,THROMBIN receptors ,G protein coupled receptors - Abstract
Protease-activated receptor 2 (PAR2) alleviates intestinal inflammation by upregulating autophagy. PAR2 also modulates tight junctions through β-arrestin signaling. Therefore, we investigated the effect of PAR2-induced autophagy on intestinal epithelial tight junctions and permeability. RT-PCR, Western blot analysis, and immunoprecipitation were performed to investigate the underlying molecular mechanisms by which PAR2 regulates autophagy and intestinal epithelial tight junctions. Inhibition of PAR2 by GB83, a PAR2 antagonist, decreased the expression of autophagy-related and tight-junction-related factors in Caco-2 cells. Moreover, inhibition of PAR2 decreased intestinal transepithelial electrical resistance. When PAR2 was activated, intestinal permeability was maintained, but when autophagy was suppressed by chloroquine, intestinal permeability was significantly increased. In addition, the prolongation of ERK1/2 phosphorylation by PAR2–ERK1/2–β-arrestin assembly was reduced under autophagy inhibition conditions. Therefore, PAR2 induces autophagy to regulate intestinal epithelial permeability, suggesting that it is related to the β-arrestin–ERK1/2 pathway. In conclusion, regulating intestinal epithelial permeability through PAR2-induced autophagy can help maintain mucosal barrier integrity. Therefore, these findings suggest that the regulation of PAR2 can be a suitable strategy to treat intestinal diseases caused by permeability dysfunction. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
12. CHRONIC COLITIS ALTERS BRAIN ACTIVITY BY INDUCING HMGB1-MEDIATED PYROPTOSIS IN MICE.
- Author
-
Mitchell, Jonathon, Kim, Su Jin, Howe, Cody, Patel, Marisa, Kim, Gayoung, Heo, Gwangbeom, Im, Eunok, and Rhee, Sang
- Published
- 2022
- Full Text
- View/download PDF
13. Posttranslational modifications as therapeutic targets for intestinal disorders.
- Author
-
Choo, Jieun, Heo, Gwangbeom, Pothoulakis, Charalabos, and Im, Eunok
- Subjects
- *
POST-translational modification , *INTESTINES , *IRRITABLE colon , *COLORECTAL cancer , *INTESTINAL diseases , *CELIAC disease , *INFLAMMATORY bowel diseases , *UBIQUITINATION - Abstract
[Display omitted] A variety of biological processes are regulated by posttranslational modifications. Posttranslational modifications including phosphorylation, ubiquitination, glycosylation, and proteolytic cleavage, control diverse physiological functions in the gastrointestinal tract. Therefore, a better understanding of their implications in intestinal diseases, including inflammatory bowel disease, irritable bowel syndrome, celiac disease, and colorectal cancer would provide a basis for the identification of novel biomarkers as well as attractive therapeutic targets. Posttranslational modifications can be common denominators, as well as distinct biomarkers, characterizing pathological differences of various intestinal diseases. This review provides experimental evidence that identifies changes in posttranslational modifications from patient samples, primary cells, or cell lines in intestinal disorders, and a summary of carefully selected information on the use of pharmacological modulators of protein modifications as therapeutic options. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
14. Interplay between the Gut Microbiota and Inflammatory Mediators in the Development of Colorectal Cancer.
- Author
-
Heo, Gwangbeom, Lee, Yunna, Im, Eunok, and Tsiaoussis, John
- Subjects
- *
COLON tumor prevention , *COLON tumors , *BIOMARKERS , *DISEASE progression , *INTERLEUKINS , *GUT microbiome , *INFLAMMATION , *ONCOGENES , *ANIMAL experimentation , *METASTASIS , *CELLULAR signal transduction , *INTERFERONS , *PROBIOTICS , *TUMOR necrosis factors , *DNA-binding proteins , *FECAL microbiota transplantation , *DISEASE risk factors ,TUMOR prevention ,RECTUM tumors - Abstract
Simple Summary: The development of colorectal cancer (CRC) can be affected by various inflammatory mediators, such as tumor necrosis factor, nuclear factor kappa B, interleukins, and interferons. Moreover, these inflammatory mediators can be reciprocally affected by gut microbiota. This review demonstrates the correlation of gut microbiota, inflammatory mediators, and CRC by summarizing studies with germ-free animals, antibiotic-treated animals, fecal microbiota transplantation, administration of specific microbiota, transgenic mice, and experimental models of CRC. It is clear that gut microbiota affect CRC through inflammatory mediators, though whether they promote or inhibit CRC depends on the context. Therefore, modulation of gut microbiota can be a good strategy for CRC prevention and control or be adjunctive therapy for CRC. Inflammatory mediators modulate inflammatory pathways during the development of colorectal cancer. Inflammatory mediators secreted by both immune and tumor cells can influence carcinogenesis, progression, and tumor metastasis. The gut microbiota, which colonize the entire intestinal tract, especially the colon, are closely linked to colorectal cancer through an association with inflammatory mediators such as tumor necrosis factor, nuclear factor kappa B, interleukins, and interferons. This association may be a potential therapeutic target, since therapeutic interventions targeting the gut microbiota have been actively investigated in both the laboratory and in clinics and include fecal microbiota transplantation and probiotics. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
15. miR-23a-3p is a Key Regulator of IL-17C-Induced Tumor Angiogenesis in Colorectal Cancer.
- Author
-
Lee, Yunna, Kim, Su Jin, Choo, Jieun, Heo, Gwangbeom, Yoo, Jin-Wook, Jung, Yunjin, Rhee, Sang Hoon, and Im, Eunok
- Subjects
VASCULAR endothelial growth factors ,COLORECTAL cancer ,VASCULAR endothelial growth factor antagonists ,NEOVASCULARIZATION ,VASCULAR endothelial cells ,VASCULAR endothelial growth factor receptors - Abstract
MicroRNAs (miRNAs) have emerged as key players in tumor angiogenesis. Interleukin-17C (IL-17C) was identified to promote colorectal cancer (CRC) progression. Therefore, we aimed to investigate the effect of IL-17C on tumor angiogenesis, the involvement of miR-23a-3p in IL-17C signaling, and the direct target gene of miR-23a-3p in CRC. In vitro and ex vivo angiogenesis, a mouse xenograft experiment, and immunostaining were performed to test the effect of IL-17C on tumor angiogenesis. ELISA, quantitative real time PCR, and gene silencing were used to uncover the underlying mechanism. IL-17C induced angiogenesis of intestinal endothelial cells, subsequently enhancing cell invasion and migration of DLD-1 cells. IL-17C-stimulated DLD-1 cells produced vascular endothelial growth factor (VEGF) to enhance angiogenesis. Moreover, IL-17C markedly accelerated xenograft tumor growth, which was manifested by substantially reduced tumor growth when treated with the VEGF receptor 2 inhibitor Ki8751. Accordingly, Ki8751 suppressed the expression of IL-17C-stimulated PECAM and VE-cadherin in xenografts. Furthermore, IL-17C activated STAT3 to increase the expression of miR-23a-3p that suppressed semaphorin 6D (SEMA6D) expression, thereby permitting VEGF production. Taken together, our study demonstrates that IL-17C promotes tumor angiogenesis through VEGF production via a STAT3/miR-23a-3p/SEMA6D axis, suggesting its potential as a novel target for anti-CRC therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
16. Cannabinoid receptor type 1 in the aging gut regulates the mucosal permeability via miR-191-5p.
- Author
-
Lee Y, Kim Y, Park S, Heo G, Chung HY, and Im E
- Subjects
- Animals, Humans, Rats, Endocannabinoids, Hydroxyurea, NF-kappa B, Permeability, Hydrogen Peroxide, MicroRNAs genetics, Receptor, Cannabinoid, CB1 genetics
- Abstract
Background: Aging is associated with a broad loss of function throughout the body, and gastrointestinal (GI) dysfunction can occur with aging. The endocannabinoid (eCB) system plays a pivotal role in various GI diseases, and alterations in the eCB system have been observed during brain and skin aging. Therefore, we investigated the putative role of the eCB system in aging-related changes in the intestine., Methods: The expression of cannabinoid receptor type 1 (CB
1 ) was investigated in rat intestinal tissues using quantitative real-time PCR. Cellular senescence was induced by hydrogen peroxide (H2 O2 ) and hydroxyurea (HU) in rat and human intestinal epithelial cells. Cellular permeability was evaluated by transepithelial electrical resistance (TEER) measurement., Results and Discussion: The expression of CB1 was decreased in the small intestine of aged rats compared to that of young rats. Senescent cells showed reduced TEER values and decreased expression of ZO-1, indicating increased intestinal permeability, which is tightly regulated by the CB1 signaling. In silico miRNA analysis suggested that ZO-1 was a direct target gene of miR-191-5p. Increased expression of miR-191-5p by HU was restored by CB1 agonist ACEA co-treatment. Moreover, NF-κB p65 activation was associated with CB1 -related miR-191-5p signaling. In conclusion, aging-induced CB1 reduction leads to increased intestinal permeability and decreased ZO-1 expression via upregulation of miR-191-5p and NF-κB p65 activation. Taken together, these results suggest that CB1 signaling may be a useful strategy to reduce intestinal permeability in aging-related and other inflammatory conditions in the gut., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Lee, Kim, Park, Heo, Chung and Im.)- Published
- 2023
- Full Text
- View/download PDF
17. Blockage of protease-activated receptor 2 exacerbates inflammation in high-fat environment partly through autophagy inhibition.
- Author
-
Her JY, Lee Y, Kim SJ, Heo G, Choo J, Kim Y, Howe C, Rhee SH, Yu HS, Chung HY, Pothoulakis C, and Im E
- Subjects
- Autophagy drug effects, Colon drug effects, Colon metabolism, Cytokines metabolism, Dextran Sulfate pharmacology, Intestinal Mucosa drug effects, Intestinal Mucosa metabolism, Receptor, PAR-2 metabolism, Apoptosis drug effects, Diet, High-Fat adverse effects, Inflammation drug therapy, Receptor, PAR-2 drug effects
- Abstract
Protease-activated receptor 2 (PAR2) regulates inflammatory responses and lipid metabolism. However, its precise role in colitis remains unclear. In this study, we aimed to investigate the function of PAR2 in high-fat diet-fed mice with colitis and its potential role in autophagy. PAR2
+/+ and PAR2-/- mice were fed a high-fat diet (HFD) for 7 days before colitis induction with dextran sodium sulfate. Deletion of PAR2 and an HFD significantly exacerbated colitis, as shown by increased mortality, body weight loss, diarrhea or bloody stools, colon length shortening, and mucosal damage. Proinflammatory cytokine levels were elevated in HFD-fed PAR2-/- mice and in cells treated with the PAR2 antagonist GB83, palmitic acid (PA), and a cytokine cocktail (CC). Damaging effects of PAR2 blockage were associated with autophagy regulation by reducing the levels of YAP1, SIRT1, PGC-1α, Atg5, and LC3A/B-I/II. In addition, mitochondrial dysfunction was demonstrated only in cells treated with GB83, PA, and CC. Reduced cell viability and greater induction of apoptosis, as shown by increased levels of cleaved caspase-9, cleaved caspase-3, and cleaved poly(ADP-ribose) polymerase (PARP), were observed in cells treated with GB83, PA, and CC but not in those treated with only PA and CC. Collectively, protective effects of PAR2 were elucidated during inflammation accompanied by a high-fat environment by promoting autophagy and inhibiting apoptosis, suggesting PAR2 as a therapeutic target for inflammatory bowel disease co-occurring with metabolic syndrome. NEW & NOTEWORTHY Deletion of PAR2 with high-fat diet feeding exacerbates colitis in a murine colitis model. Proinflammatory effects of PAR2 blockage in a high-fat environment were associated with an altered balance between autophagy and apoptosis. Increased colonic levels of PAR2 represent as a therapeutic strategy for IBD co-occurring with metabolic syndrome.- Published
- 2021
- Full Text
- View/download PDF
18. 5-Aminosalicylic Acid Azo-Coupled with a GPR109A Agonist Is a Colon-Targeted Anticolitic Codrug with a Reduced Risk of Skin Toxicity.
- Author
-
Jeong S, Lee H, Kim S, Ju S, Kim W, Cho H, Kim HY, Heo G, Im E, Yoo JW, Yoon IS, and Jung Y
- Subjects
- Animals, Anti-Inflammatory Agents, Non-Steroidal chemistry, Anti-Inflammatory Agents, Non-Steroidal therapeutic use, Anti-Inflammatory Agents, Non-Steroidal toxicity, Cell Line, Tumor, Chromatography, Liquid, Colitis metabolism, Colon pathology, Drug Delivery Systems, Humans, Inflammatory Bowel Diseases drug therapy, Inflammatory Bowel Diseases metabolism, Interleukin-10 metabolism, Male, Mesalamine blood, Mesalamine therapeutic use, Mice, NF-kappa B metabolism, Nicotinic Acids blood, Nicotinic Acids therapeutic use, Rats, Rats, Sprague-Dawley, Sulfasalazine pharmacology, Sulfasalazine therapeutic use, Anti-Inflammatory Agents, Non-Steroidal administration & dosage, Colitis drug therapy, Colon drug effects, Receptors, G-Protein-Coupled agonists
- Abstract
To develop a 5-aminosalicylic acid (5-ASA)-based anticolitic drug with enhanced therapeutic activity, a colon-targeted codrug constituting 5-ASA and a GPR109A agonist was designed. 5-ASA azo-coupled with nicotinic acid (ASA-azo-NA) was synthesized, and the colon specificity and anticolitic effects were evaluated. Approximately 89% of ASA-azo-NA was converted to 5-aminonicotinic acid (5-ANA) and 5-ASA after 24 h of incubation in the cecal contents. 5-ANA was identified as a GPR109A agonist (concentration that gives half-maximal response (EC
50 ): 18 μM) in a cell-based assay. Upon oral gavage of ASA-azo-NA (oral ASA-azo-NA) and sulfasalazine (oral SSZ), a colon-targeted 5-ASA prodrug, cecal accumulation of 5-ASA was comparable, and 5-ANA was barely detectable in the blood, while it was detected up to 62.7 μM with oral 5-ANA. In parallel, oral ASA-azo-NA did not elicit an adverse skin response. In murine macrophage and human colon carcinoma cells, activation of GPR109A by 5-ANA elevated the level of the anti-inflammatory cytokine IL-10, suppressed NF-κB activation, and potentiated the inhibitory activity of 5-ASA on NF-κB. Oral ASA-azo-NA ameliorated rat colitis and was more effective than oral SSZ, which were substantially blunted following cotreatment with the GPR109A antagonist, mepenzolate. In conclusion, ASA-azo-NA is a colon-targeted anticolitic codrug with a reduced risk of skin toxicity induced by the GPR109A agonist, therapeutically surpassing a current 5-ASA-based anti-inflammatory bowel disease drug in a rat colitis model.- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.